Creating new small molecules and nucleic acids to treat diseases
Official title: SMALL-MOLECULE AND NUCLEIC ACID ENGINEERING TOWARD MOLECULAR DESIGNS OF THERAPEUTIC POTENTIAL
Funded at Rutgers, the State Univ of N.j. · NIH-10941353 · Data updated 2026-11-12
This study is working on new treatments for cancer by creating special tiny molecules and RNA-based therapies that can more precisely target the disease, aiming to make treatments more effective and with fewer side effects for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rutgers, the State Univ of N.j. NIH-funded |
| Lab location | 1 site (Piscataway, United States) |
| Project start | September 1, 2024 |
| Project end | August 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $388,621 |
| NIH project number | 1R35GM155002-01 |
| Project ID | NIH-10941353 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with cancers or inflammatory conditions that may benefit from novel therapeutic approaches.
✕Less likely to help
Patients with non-malignant conditions or those not responsive to molecular therapies may not receive benefits from this research.
What this research studies
This research focuses on designing innovative small molecules and nucleic acid polymers that can effectively target and treat diseases, particularly cancers. By combining advanced synthetic organic chemistry with nucleic acid engineering, the project aims to develop highly selective and stable therapeutic agents. The approach includes creating targeted RNA degraders and biostable mimics of RNA-cleaving ribozymes, which could enhance treatment efficacy and reduce side effects for patients. The research also explores the modulation of critical pathways involved in inflammation and cancer.
Why it matters
Potential benefit: If successful, this research could lead to more effective and targeted therapies for cancer and other diseases, improving patient outcomes.
How similar studies have gone: Other research has shown promise in developing targeted therapies using similar molecular engineering approaches, indicating potential for success in this area.
Where this research is happening
-
Rutgers, the State Univ of N.j.
Piscataway, United States Active
Researchers
- Principal investigator: Izgu, Enver C — Rutgers, the State Univ of N.j.
- Study coordinator: Izgu, Enver C
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.